The Familial Chylomicronemia (Type I Hyperlipoproteinemia) drugs in development market research report provides comprehensive information on the therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Familial Chylomicronemia (Type I Hyperlipoproteinemia). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) by six companies/universities/institutes. The top development phase for Familial Chylomicronemia (Type I Hyperlipoproteinemia) is phase iii with four drugs in that stage. The Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline products market are: Ionis Pharmaceuticals, Arrowhead Pharmaceuticals and iMetabolic Biopharma.

The key targets in the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline products market include Apolipoprotein C III (APOC3), Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3), and Angiopoietin Related Protein 4 (Angiopoietin Like Protein 4 or Hepatic Fibrinogen/Angiopoietin Related Protein or ANGPTL4).

The key mechanisms of action in the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline product include Apolipoprotein C III (APOC3) Inhibitor with three drugs in Filing rejected/Withdrawn. The Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline products include three routes of administration with the top ROA being Subcutaneous and five key molecule types in the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline products market including Antisense Oligonucleotide, and Antisense RNAi Oligonucleotide.

Familial Chylomicronemia (Type I Hyperlipoproteinemia) overview

Familial chylomicronemia syndrome (hyperlipoproteinemia type 1) is an inherited condition that disrupts the breakdown of fats in the body, causing high levels of fat to build up in the blood. It is characterized by pancreatitis, abdominal pain, enlargement of the liver and spleen (hepatosplenomegaly), and small yellow skin lesions called eruptive xanthomas. Familial chylomicronemia syndrome is caused by genetic changes in the LPL gene that are inherited in an autosomal recessive pattern.

For a complete picture of Familial Chylomicronemia (Type I Hyperlipoproteinemia)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.